DEF 14A: Terns Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting

Terns Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders online on June 10, 2024, to elect directors and ratify the selection of its independent accounting firm.

Summary

• Terns Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders online on June 10, 2024.
• Stockholders of record as of April 18, 2024, are eligible to vote.
• The meeting will address the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and any other business that may properly come before the meeting.
• The board of directors recommends voting FOR the election of the director nominees and FOR the ratification of the accounting firm appointment.
• The company's outstanding voting securities as of the record date were 64,674,780 shares of common stock.
• The proxy statement and annual report are available online at www.envisionreports.com/TERN.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for stockholders to make informed decisions.

Positives

• The Annual Meeting will be held entirely online to allow greater participation and improved communication and provide cost savings for our stockholders and the Company.
• The board of directors has determined that all members of the audit committee are independent under the Nasdaq Listing Rules and Rule 10A-3(b)(1) of the Exchange Act.
• The board of directors has determined that Jill Quigley is an audit committee financial expert as such term is currently defined in Item 407(d)(5) of Regulation S-K.

Future Outlook

The company is seeking stockholder approval for the election of directors and ratification of the independent accounting firm.

Management Comments

• On behalf of the board of directors, I would like to express our appreciation for your interest in Terns.
• The Annual Meeting will be held entirely online to allow greater participation and improved communication and provide cost savings for our stockholders and the Company.

Industry Context

This is a standard proxy statement for a publicly traded company, outlining the business to be conducted at the annual meeting and providing information to stockholders to make informed voting decisions.

Comparison to Industry Standards

• The director compensation and audit fee structures appear to be within the typical range for similarly sized biopharmaceutical companies.
• The company's corporate governance practices, such as having an audit committee and a code of ethics, are standard for publicly traded companies.

Management Changes

Corporate Governance

Related Party Transactions

• The company has entered into employment agreements with its executive officers.
• The company has entered into indemnification agreements with certain of its current directors, executive officers and certain other employees.

Stakeholder Impact

• Stockholders are being asked to vote on the election of directors and the ratification of the independent accounting firm.
• The outcome of the votes will impact the composition of the board of directors and the selection of the company's auditor.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 10, 2024, and announce the voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Ernst & Young, Audit Committee, Corporate Governance, Terns Pharmaceuticals